News

Embody Advances Biologic Augmentation Market with First-Of-Its-Kind Collagen Implant

Embody, Inc., a privately-held medical device company developing novel collagen-based technologies for soft tissue injury and repair, announced today the expansion and clinical use cases of TAPESTRY® Biointegrative Implant in the U.S. market. TAPESTRY Biointegrative Implant is the first collagen-based implant with a bioengineered micro-architecture and biostimulative, highly organized type I collagen chemistry specifically designed for the management and protection of tendon injuries. The unique combination of the collagen chemistry and structural integrity provides unparalleled clinical utility and sizing across a broad range of tendon applications including, but not limited to, foot and ankle, knee, and shoulder procedures.

“Catastrophic failure and clinical dysfunction associated with poor subscapularis tendon healing rates following shoulder arthroplasty leads to suboptimal functional outcomes and costly re-operations for our patients,” said Amit Nathani, MD, an Orthopaedic Surgeon and Shoulder Specialist in Santa Barbara, California. “TAPESTRY combines the benefits of collagen-based chemistry with unique sizing, hydrophilicity, and handling characteristics appropriate to augment total shoulder procedures, offering the potential to enhance healing and reduce soft tissue failures.”

“There is a strong clinical need for a better solution to treat tendon injury of the foot & ankle,” said Alan Ng, DPM, FACFAS, at Advanced Orthopedic & Sports Medicine Specialists in Denver, CO. “The TAPESTRY implant is unlike anything else I have used in its ability to form new, dense collagenous tissue at the site of the implantation combined with its superior handling and sizing make it ideal for a variety of challenging tendon procedures including Achilles and paroneal tendons.”

“Following the initial surgical procedures with TAPESTRY, we are seeing continued use and expanded interest across a wide range of demanding tendon applications including subscapularis, patellar, peroneal and Achilles tendons where formative products have lacked the combination of handling, structural integrity, and a biostimulative chemistry,” said Jeff Conroy, CEO of Embody. “We continue to expand our range of sizes and shapes to rapidly accommodate every surgeon’s need.”

Recent News

04/01/2025

ReAlta Life Sciences Announces Appointment of Distinguished Immunologist, Laurie Glimcher, M.D., to Board of Directors

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases,  announced the appointment of Laurie Glimcher, M.D., to its Board of Directors, effective immediately. Dr. Glimcher is a distinguished immunologist widely renowned for her work in cancer

03/31/2025

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process. Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and

03/26/2025

New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation

Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products — making the supply of medicines for US patients and